Sign in to fuzzto save your conversations, follow your research and come back anytime.

Jubilant Pharmova Limited is an integrated global pharmaceutical and life sciences company. It operates in segments including Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and Manufacturing Organisation, and Proprietary Novel Drugs. The company manufactures and supplies Active Pharmaceutical Ingredients, Solid Dosage Formulations, Radiopharmaceuticals, and Allergy Therapy Products. It has 6 US FDA approved manufacturing facilities in India, USA and Canada, and a network of over 48 radiopharmacies in the USA. Jubilant Pharmova provides drug discovery and development services, and is working on addressing unmet medical needs in oncology and autoimmune diseases. The company has filed numerous Drug Master Files in various countries and has expanded its manufacturing and research capabilities in recent years.
In the news

Jubilant Pharmova gets USFDA approval for new fill-and-finish line

Jubilant Pharmova Q1 profit drops 45% to ₹56.5 crore

Jubilant Pharmova gets USFDA nod for Pantoprazole suspension

USFDA Completes Inspection of Jubilant HollisterStier Unit

Jubilant Pharmova Q4 profit drops 21% to ₹119.3 cr, Nuvama maintains BUY

Market Rally Continues: 6 stocks for March 25 amid Iran de-escalation
Company insights, generated from the most recent coverage.
Line 3 focus on complex biologics (80% of products) commands price premiums and creates high switching costs, driving durable customer relationships and above-normalized EBITDA margins.
FDA approval for Line 3 at Spokane enables commercial batch production in late FY27, accelerating peak revenue potential ($80-90M) by 1.5-2 years vs original projections.